

Cambio constitutes the operating entities under Sanolium AB. All figures in () refer to the comparable figures from previous year. The pro forma for the full year 2019 includes operating activities from January 1st to February 20th. The pro forma prior to 2019 refers to Cambio Group operating activities in periods prior to 2019.

Revenue increased to 686.0 (pro forma 586.2) MSEK in the full year 2020, corresponding to a growth of 17.0 %


Q4, October - December 2020

- Revenue amounted to 167.2 (184.2) MSEK in the fourth quarter, representing a decline of -9.2%
- Adjusted EBITDA amounted to 12.2 (41.7) MSEK, representing a decline of -70.7%
- Revenue recognition is negatively affected by the Covid-19 situation


January - December 2020

- Revenue during January - December amounted to 686.0 (20 Feb – 31 Dec, 2019; 518.9) MSEK
- Adjusted EBITDA amounted to 156.1 (20 Feb -31 Dec 2019; 108.8) MSEK

Q4, revenue



Pro forma revenue, MSEK



Key figures

MSEK	Q4 2020	Q4 2019	Jan-Dec 2020	Feb-Dec 2019
Revenue	167.2	184.2	686.0	518.9
Adjusted EBITDA	12.2	41.7	156.1	108.8
Adjusted EBITDA-margin	7.3%	22.6%	22.8%	21.0%
EBIT	-39.2	-2.8	-19.5	-96.2
Financial net	-5.4	-2.7	-25.4	-16.6
Income before tax	-44.6	-5.5	-44.9	-112.8
Net income	-43.1	-10.4	-44.1	-105.7

CEO's Comments

The increased demand for our solutions reflects the need for increased digitalization in health- and social-care. The Nordic regions and municipalities need to invest more in IT than they have done historically. Cambio has the products and services to bridge the technical gap that the regions and municipalities face, and to enable tomorrow's health- and social-care. Together with our customers we contribute to a better and healthier society.

About Cambio

Cambio is well positioned to become the Nordic leader within eHealth. Today we principally serve Nordic regions and municipalities by delivering their core healthcare IT system.

The constantly growing and aging population creates a need for increased productivity and efficiency in health- and social-care and in a world with limited resources this can be achieved by increased digitalization.

The growing gap between the available technologies and the technical solutions used by healthcare providers today can and will be bridged through Cambio's solutions.

About fourth quarter

As a result of the spread of the Corona virus many people are living with challenging conditions and many have lost their lives.

The impact of Covid-19 on society and businesses continues to be severe. Cambio's priorities under the current circumstances are to support our customers, to ensure our products fulfil their purpose without any interruptions and to protect the health and safety of our employees.

Cambio has, together with our existing customers, taken actions to directly address Covid-19 effects to make it possible to decrease administrative time, share information with municipalities, provide more intensive care beds and to offer the best vaccination record system available on the market.

Direct interactions with our customers remain in conjunction with the Covid-19 situation at a low level making it harder to sell new projects and obtain delivery approvals. We have also, seen negative impact on our operational efficiency and productivity. This has impacted some project timings and

therefore revenue recognition. This is all in line with previous communication.

We have had intensive discussions with regions about Cambio's vaccination solution MittVaccin. At the time of publishing this report 7 out of Cambio's 17 regions have signed up to use MittVaccin.

We look forward to strengthening our position as a natural partner to our customers, to help them do their job more efficiently!



Peter Gille, CEO

Fourth quarter

Revenue in the fourth quarter amounted to 167.2 (184.2) MSEK, representing a decline of -9.2%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional services revenue are attributable to the development of the existing product as well as the SUSSA project.

Adjusted EBITDA in the fourth quarter amounted to 12.2 (41.7) MSEK resulting in an adjusted EBITDA margin of 7.3 (22.6)%.

Employee related expenses amounted to 129.3 (118.1) MSEK, corresponding to an increase of 9.5%. The number of fulltime employees rose to 723 in the fourth quarter, an increase of 9.7% from the comparable figure last year. The number of employees by end of the fourth quarter amounted to 748 of which 371 were employed in Sweden and 326 were women.

Depreciation and amortization amounted to 36.3 MSEK, of which 27.6 MSEK refers to amortization of intangible assets with regards to M&A activities, 2.8 MSEK refers to financial leases and 3.0 MSEK refers to amortization of capitalized R&D. The remaining depreciation of tangible assets amounted to 2.9 MSEK.

Non-recurring items amounted to 15.1 MSEK, consisting of 5.3 MSEK relating to the introduction of a new ERP system, 4.8 MSEK relate to organisational adjustments and 5.0 MSEK relate to other.

Significant events and outlook

No significant events to report about in the fourth quarter.

Covid-19 implications on the business

Cambio provides business-critical software that many doctors and nurses in Sweden use on a daily basis to deal with healthcare matters, including the current Covid-19 pandemic. Cambio's most important task under the current circumstances is to ensure our products fulfil their purpose without any interruptions or down time.


Direct interactions with our customers remain at a low level making it harder to sell new projects and obtain delivery approvals. This continues to impact project timings and therefore revenue recognition in the fourth quarter. We have also seen some impact on our operational efficiency and productivity.



Long-term outlook

In response to the global trend of a constantly growing and aging population there is a real need to invest in health- and social-care. In a world with limited resources these areas of care face increasing pressure to become more productive and efficient, resulting in a greater demand for digitalization. A key pillar of the digital transformation is communication and in particular the way in which health- and social-care institutions interact. A solid IT infrastructure is key to the development of a future-proof way of working.

Today there is a sizeable gap between the available technologies and the technical solutions used by health- and social-care organizations. Cambio's solutions address that technology gap, resulting in a strong and sustainable demand for our offerings on a global scale.



Liquid funds and cash conversion

By the end of December, Cambio's cash amounted to 398.5 MSEK. Additionally, Cambio has a non-utilized credit facility amounting to 100.0 MSEK.

Cambio's strong cash conversion is driven by maintenance fees invoiced one year in advance, and a low level of capital expenditures and capitalized R&D that has been stable over recent periods. Since most of the invoices are issued in the fourth quarter of each year, a quarterly comparison of Cambio's cash conversion does not provide for an adequate and fair picture.

Cash conversion by the end of 2020 amounted to 115.2 % (133.0 %). During the past 6 years cash conversion has been above 100.0 %.

M&A

In September Cambio continued to deliver on its M&A strategy with the acquisition of MittVaccin (company reg. no. 556883-3411). The purchase consideration amounts to 36.1 MSEK of which 26.8 MSEK was paid in cash and the remaining 9.3 MSEK in newly issued shares. Acquired net assets amounted to -0.7 and surplus value to be allocated amounted to 36.8. The main part (31.2) is residual Goodwill.

Leverage

By the end of the fourth quarter the leverage amounted to 3.1 x LTM Q4-20 EBITDA. The leverage is calculated according to the table on the right-hand side. This calculation is in line with the definitions agreed in the existing bond terms.

Balance sheet

Cambio's fixed assets amount to 79.0%, of which 76.3% refer to intangible assets subject to impairment tests. Management believes that these assets provide for a solid foundation to drive future profitability and growth.

The external interest-bearing loans amounted to 548.6 MSEK of which 497.6 MSEK refers to utilized bond facility and 51.0 MSEK refers to financial lease liability with regards to IFRS 16.

The Senior Secured 500 MSEK bond rolls with a 3-months-STIBOR + 4.25%. In order to reduce that exposure Sanolium AB has entered into an Interest Rate Cap Transaction. In conjunction to that Sanolium AB has secured the floating part of the interest on half of the bond value, 250 MSEK, to a maximum of 0.188%. The termination date of this derivative is 26-03-2023.

Products and technology

Cambio's vision is to enable tomorrow's healthcare today. This will be achieved in close cooperation with regions, municipalities and private companies and with continued investments in innovation and technology to further strengthen our product offering.

Cambio COSMIC, is a healthcare information system used in university hospitals, primary care clinics and community care homes. Cambio COSMIC is built on a modern proprietary platform with a wide range of associated subsystems supporting various healthcare disciplines.



Cambio VIVA is used in municipalities. It is an operating system used to coordinate the activities and processes of social services, healthcare and care professionals. VIVA's proprietary platform enables a digital working environment supporting work processes and organizational developments and changes.

In addition to these two major product categories, Cambio offers other connected services and solutions. Cambio is also preparing and planning to deliver Manage Service offerings in the future.

Leverage, MSEK

Liability	497.6
Financial lease K3	2.7
Cash	-398.5
80 percent of deferred income	330.0
Net debt (Liability-surplus cash)	431.8
Applicable LTM EBITDA	138.2
Leverage (Net debt/EBITDA)	3.1x

Balance sheet



Cambio COSMIC health care information system. Improving the efficiency of daily tasks and patient outcomes for 100.000 users.

Customers

Following the newly agreed contract with the option regions with the Sussa customer group Cambio will cover 17 out of 21 regions in Sweden, which means that Cambio would cover 46.3% of the Swedish population and 51.0% of the end users.

17 of 21
regions

Today, Cambio has active users in 8 out of 21 regions in Sweden, covering 22.7% of the Swedish population and 26.0% of the end users. Cambio VIVA covers 39 out of the 290 municipalities in Sweden, covering 14.6% of the Swedish population and 12.0% of the end users.

The ambition is to increase the number of customers and to increase the depth and breadth of our product offering so that end users benefit from as much support and help as possible. In Denmark, Cambio offers a wide range of products and our ambition is to reach more end-users with relevant offerings.

Sustainability

Cambio's business model is built on accelerating sustainability in organizations within health- and social-care. Cambio's sustainability report is published on www.cambiogroup.com under Investor Relations.



Market and legislation

The market for delivering e-Health software services is regulated by the Medical Device Directive MDD 93/42/EEC. This regulation will be replaced in 2021 by the Medical Device Regulation MDR 2017/45.

Almost all tenders ask for a certified Quality Management System, an active Environmental work, and an active Information Security Work. Cambio has the most relevant ISO certifications for the business, such as ISO 9001, 14001, 20000 and 27001.

Most of our customers are publicly financed organizations who are subject to rules and regulations regarding public tender processes. In conjunction with this Cambio needs to be fully aware of those formal processes and act within those frameworks.

Since Cambio handles sensitive information about specific patients we comply with GDPR.

Risks

The group's operations are exposed to a number of financial risks such as market risks (currency risk and interest risk), credit risk and liquidity risk. The group aims to minimize potential adverse effects of these risks on the group's financial results.

The group's exposure to currency risk consists primarily of transactions taking place in foreign currencies between subsidiaries of Cambio. The company does not use derivative instruments in order to reduce currency risks at present.

Since Sanolium AB in September 2019 issued a senior secured bond for a total amount of 500 MSEK, the company is exposed to interest rate trends. The bond terms give the investors a yield of STIBOR 3M + 4.25%. In order to reduce that exposure Sanolium AB has entered into an Interest Rate Cap Transaction with DNB BANK ASA. The implication of the transaction is that Sanolium AB has secured the floating part of the interest on half of the bond value, 250 MSEK, to a maximum of 0.188%. The termination date of the derivative is 26-03-2023. The derivative is valued at fair value according to a technique based on fully observable market information.

For a more detailed description of the risks mentioned above and other risks and uncertainties, please refer to the Annual Report 2019.

Transactions with related parties

Sanolium AB is the senior parent company in the group. Related parties consist of all subsidiaries and senior executives in the group and their Related parties. Transactions take place on market terms.

The extent and nature of transactions with related parties in the period is consistent with previous year's transactions with related parties, as described in the 2019 annual report.

This interim report has not been subject to external audit.

Stockholm, 20 February 2021

Peter Gille

CEO

Consolidated income statement


MSEK	Q4 2020	Q4 2019	Jan-Dec 2020	Feb-Dec 2019
License revenue	28.0	40.9	97.1	75.2
Maintenance revenue	104.6	99.6	419.0	334.1
Professional services	19.9	30.0	118.8	77.9
Other revenue	14.7	13.7	51.1	31.7
Revenue	167.2	184.2	686.0	518.9
Cost of services provided	-14.1	-13.2	-52.3	-28.8
Gross profit	153.1	171.0	633.7	490.1
Employee related expenses	-129.3	-118.0	-439.6	-342.2
Facilities	-2.9	-1.8	-7.2	-6.9
Marketing	-2.2	-1.6	-4.6	-6.3
Travel	-0.3	-2.2	-2.7	-7.8
Other expenses	-6.2	-5.7	-23.5	-18.1
Total operating expenses	-140.9	-129.3	-477.6	-381.3
Adjusted EBITDA	12.2	41.7	156.1	108.8
Depreciation	-36.3	-48.6	-146.3	-131.9
Adjusted EBIT	-24.1	-6.9	9.8	-23.1
Non recurring items	-15.1	4.1	-29.3	-73.1
EBIT	-39.2	-2.8	-19.5	-96.2
Financial net	-5.4	-2.7	-25.4	-16.6
Income before tax	-44.6	-5.5	-44.9	-112.8
Tax	1.5	-4.9	0.8	7.1
Net Income	-43.1	-10.4	-44.1	-105.7

Consolidated statement of Comprehensive income

MSEK	Q4 2020	Q4 2019	Jan-Dec 2020	Feb-Dec 2019
Net Income/loss	-43.1	-10.4	-44.1	-105.7
Exchange differences in translating foreign operations	-5.7	-0.9	-9.0	-0.4
Total comprehensive income for the period	-48.8	-11.3	-53.1	-106.1
<i>Total comprehensive income attributable to:</i>				
Equity holders of the parent company	-48.8	-11.3	-53.1	-106.1
Non controlling interest	NA	NA	NA	NA

Non-Recurring items relating to:

MSEK	Q4 2020	Q4 2019	Jan-Dec 2020	Feb-Dec 2019
Contribution from decided divestment		9.8	-3.6	-8.0
Advisory fees mergers and acquisitions			-1.5	-35.5
New ERP system	-5.3		-12.8	
Refinancing				-23.9
Organisational adjustments	-4.8		-4.8	
Other	-5.0		-6.6	
Total non-recurring items	-15.1	4.1	-29.3	-73.1



The app Min Hälsa contains all information a patient would need in relation with healthcare.

Consolidated Balance Sheet

MSEK	2020-12-31	2019-12-31
<i>Fixed Assets</i>		
Intangible assets	2,049.0	2,094.7
Tangible assets	18.1	15.6
Right-of-use assets	50.6	26.1
Financial assets	3.2	3.7
Total Fixed Assets	2,120.9	2,140.1
<i>Current Assets</i>		
Inventory	0.3	0.3
Work in progress	55.7	66.0
Accounts receivables	76.4	94.4
Other receivables	6.0	7.3
Tax receivables	8.9	2.6
Prepaid expenses, accrued income	17.3	22.2
Cash	398.5	337.1
Total Current Assets	563.1	529.9
Total Assets	2,684.0	2,670.0
<i>Equity</i>		
Share capital	1.7	1.7
Non-restricted equity	1,143.5	1,258.2
Net income for the period	-44.1	-105.7
Total Equity	1,101.1	1,154.2
Provisions	15.0	12.9
Total Financial Liabilities	497.6	497.3
<i>Other liabilities</i>		
Advance payments	32.5	60.8
Accounts payable	15.0	16.2
Lease liabilities	51.1	26.7
Deferred/ Current Tax liabilities	337.6	350.9
Other liabilities	141.0	127.3
Accrued expenses	80.6	51.7
Deferred income	412.5	372.0
Total Other Liabilities	1,070.3	1,005.6
Total Equity and Liabilities	2,684.0	2,670.0

Changes in group equity

MSEK	Jan-Dec 2020	Feb-Dec 2019
Opening Balance	1,154.2	
Total comprehensive income for the period	-53.1	-106.1
Total change excluding owner transactions	1,101.1	-106.1
Non-cash issue		160.9
Shareholder contributions		1,099.4
Equity at the end of the period	1,101.1	1,154.2
Attributable to equity holders of the parent company	1,101.1	1,154.2
Non-controlling interest	N/A	N/A

Consolidated cashflow statement

MSEK	Jan-Dec 2020	Feb-Dec 2019
Income after financial items	-44.9	-112.8
Adjusted for non-cash items	137.8	265.5
Taxes paid	-9.0	-12.5
Changes in working capital	68.5	12.1
Cash flow from operating activities	152.4	152.3
Investments in intangibles/tangibles	-45.9	-27.1
Acquisition of shares in subsidiaries and associations	-26.2	-1,372.4
Cashflow from investing activities	-72.1	-1,399.5
Shareholder contributions		1,099.7
Bond issue		500.0
Lease payments	-18.9	-15.4
Cashflow from financing activities	-18.9	1,584.3
Changes in cash and cash equivalents	61.4	337.1
Opening cash and cash equivalents balance	337.1	
Cash and cash equivalents by end of the period	398.5	337.1

Consolidated Income Statement – Pro Forma

MSEK	Jan-Dec 2020	Jan-Dec 2019
License revenue	97.1	79.5
Maintenance revenue	419.0	386.8
Professional services	118.8	84.3
Other revenue	51.1	35.6
Revenue	686.0	586.2
Cost of services provided	-52.3	-32.2
Gross profit	633.7	554.0
Employee related expenses	-439.6	-386.6
Facilities	-7.2	-8.2
Marketing	-4.6	-6.8
Travel	-2.7	-9.5
Other expenses	-23.5	-20.6
Total operating expenses	-477.6	-431.7
Adjusted EBITDA	156.1	122.3
Depreciation	-146.3	-158.4
Adjusted EBIT	9.8	-36.1
Non recurring items	-29.3	-73.1
EBIT	-19.5	-109.2
Financial net	-25.4	-20.6
Income before tax	-44.9	-129.8
Tax	0.8	10.2
Net Income	-44.1	-119.6

Pro forma figures include the operational figures prior to February 20, 2019 when the Sanolium group was founded.

Since the structure in the interim report differs from the annual report, in the table below the year to date consolidated income statement is shown in the annual report format.

Consolidated Income Statement – Annual report format

MSEK	Jan-Dec 2020	Feb-Dec 2019
Net sales	635.0	492.3
Other revenue	51.1	31.1
Capitalized R&D	35.2	19.1
Total	721.3	542.5
Other external expenses	-188.2	-145.6
Personnel cost	-406.3	-296.6
Depreciation	-146.3	-133.9
Operating income	-19.5	-33.6
Financial net	-25.4	-79.2
Income before tax	-44.9	-112.8
Tax	0.8	7.1
Net Income	-44.1	-105.7

Segment reporting

The group recognizes only a single segment in accordance with the definition of operating segment in IFRS 8. The starting point for identifying operating segments on which separate information can be provided are the internal reports to and monitoring by the group management. The group management monitors operating income for the entire business as one operating segment.

Timing of revenue

MSEK	Q4 2020	Q4 2019	Jan-Dec 2020	Feb-Dec 2019
Timing of revenue recognition				
At a point in time	62.6	84.6	267.0	184.8
Over time	104.6	99.6	419.0	334.1
	167.2	184.2	686.0	518.9

"At a point in time" is defined as revenue correlated to working hours while "over time" is not.

Intangible assets

MSEK	Capitalised development expenditure	Customer contracts/ accrued revenues	Trademarks	Technology	Goodwill	Total
At 31 Dec 2019	78.9	573.6	87.7	918.1	436.4	2,094.7
Acquisitions for the period	41.7	6.3	0.4	0.3	31.2	79.9
Depreciation for the period	-12.4	-43.4		-65.0		-120.8
Exchange rate changes	-0.8			2.1	-6.1	-4.8
At 31 Dec 2020	107.4	536.5	88.1	855.5	461.5	2,049.0

APPLICABLE ACCOUNTING RULES

Sanolium AB complies with IFRS standards and interpretations (IFRIC) as adopted by the EU. This Interim Report has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company's financial statements have been prepared in accordance with RFR 2. The accounting policies applied are consistent with those presented in the Annual Report for 2019, except for the adoption of standard amendments effective as of January 1, 2020. The amendments are not expected to have any material impact on the financial statements.

Detailed information about the Group's accounting and valuation principles can be found in the Annual Report for 2019 which is available on www.cambio.se.

This interim report refers to certain key performance indicators which Cambio and others use when evaluating the performance of Cambio. These are referred to as alternative performance measures (APMs) and are not defined under IFRS. The figures give management and investors important information and enable both to analyze Cambio's business and trends. The APMs are not meant to replace but to complement the performance measures defined under IFRS.

Parent company

Sanolium AB is a holding company that invests in fast-growing companies within the e-health industry. The company is one of the largest e-Health companies in Northern Europe and has the ambition to grow faster than the market through organic opportunities as well as acquisitions. This should be done in a profitable and sustainable manner. Sanolium AB's operational subsidiaries' vision is to enable tomorrow's healthcare today.

The operating entities mainly deliver products and services in Sweden under the names Cambio COSMIC and Cambio VIVA.

Sanolium AB has no employees.

Income Statement Parent Company

MSEK	Q4 2020	Q4 2019	Jan-Dec 2020	Feb-Dec 2019
Other revenue			2.9	3.1
Revenue			2.9	3.1
Employee related expenses	-0.4	-0.2	-3.3	-3.3
Other expenses	-0.1		-0.1	-0.1
Total operating expenses	-0.5	-0.2	-3.3	-3.4
Adjusted EBITDA	-0.5	-0.2	-0.4	-0.3
Non recurring items		-0.9	-0.8	-24.8
EBIT	-0.5	-1.1	-1.2	-25.1
Financial net	-6.8	-7.3	-26.6	-18.6
Net Income	-7.3	-8.4	-27.8	-43.7



Balance sheet Parent Company

MSEK	2020-12-31	2019-12-31
<i>Fixed Assets</i>		
Financial assets	1,814.8	1,815.7
Total Fixed Assets	1,814.8	1,815.7
<i>Current Assets</i>		
Other receivables	0.1	1.6
Other receivables - Group	7.4	4.0
Prepaid expenses and accrued income	0.2	0.1
Cash	6.1	10.8
Total Current Assets	13.8	16.5
Total Assets	1,828.6	1,832.2
<i>Equity</i>		
Share capital	1.7	1.7
Non-restricted equity	1,215.2	1,259.0
Net income for the year	-27.8	-43.7
Total Equity	1,189.1	1,217.0
Total Financial Liabilities	497.6	496.9
<i>Other liabilities</i>		
Other liabilities	99.4	99.4
Other liabilities - Group	42.0	18.6
Accrued expenses	0.5	0.3
Total Other Liabilities	141.9	118.3
Total Equity and Liabilities	1,828.6	1,832.2

Changes in Parent company equity

MSEK	Jan-Dec 2020	Feb-Dec 2019
Opening Balance	1,217.0	
Total comprehensive income for the period	-27.9	-43.7
Total change excluding owner transactions	1,189.1	-43.7
New share issue		0.1
Non-cash issue		160.9
Shareholder contributions		1,099.7
Equity at the end of the period	1,189.1	1,217.0
Attributable to equity holders of the parent company	1,189.1	1,217.0
Non-controlling interest	N/A	N/A

Parent company cash flow

MSEK	Jan-Dec 2020	Feb-Dec 2019
Income after financial items	-27.8	-43.7
Changes in working capital	23.2	112.2
Cash flow from operating activities	-4.6	68.9
Acquisition of shares in subsidiaries and associations		-1,654.8
Cashflow from investing activities		-1,654.8
Shareholder contributions		1,099.7
Bond issue		497.0
Cashflow from financing activities		1,596.7
Changes in cash and cash equivalents	-4.6	10.8
Opening cash and cash equivalents balance	10.8	
Cash and cash equivalents by end of the period	6.1	10.8

Definitions

Adjusted EBIT

Income before non recurring items, financial net and tax.

Adjusted EBITDA

Income before depreciation, non-recurring items, financial net and tax.

Adjusted EBITDA margin

Adjusted EBITDA as a percentage of revenue.

Cash conversion

Operating cash flow divided by adjusted EBITDA.

EBIT

Income before financial net and tax.

Non-recurring items

Items excluded from the normal operating items e.g restructuring costs, costs related to introduction of a new ERP system, M&A related costs and costs regarding refinancing or to set a financing structure (excluding interest on external debt).

Operating cash flow

Adjusted EBITDA minus capital expenditures, capitalized R&D and net working capital changes.

Financial calendar

Annual General Meeting, 2021-05-04
Interim report Q4. Full year, 2021-02-19
Interim report Q1, January-March 2021-05-31
Interim report Q2 January-June, 2021-08-19
Interim report Q3 January-September, 2021-11-30



Presentation of the interim report

Cambio's interim reports will be published at cambio.com at each of the dates stipulated above.

Information

For further information, please contact:
Fredrik Rüdén, CFO +46 760 018 422
fredrik.ruden@cambio.se



Sanolium AB

Cambio Healthcare Systems AB
Drottninggatan 89
113 60 Stockholm



+46 8 691 49 00
info@cambio.se